The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Spacex was 9.1% of EWI at last report
I think I could agree with you Legache but I am sure Jay and co have other ideas but they need to convince the market.As far as Egyptian proceeds are concerned,the assets are valued at $25001 in half year 23 accounts.After the write downs in 2022 I suggest this is not an overvaluation and additional income will have been accrued in view of capital restrictions.
I have never come across business sale below the asset value suggesting a price of £20m compared to £8.7 for the whole company.What do you think ?
Legache we all have to make our own minds up.The facts are the facts.The main issues here are the Egyptian sale and the dilution on the conversion of the Aleph loan.Past history of previous management incompetence is just that,history. In my opinion the new guys are on the ball,savvy on finance and dealing.In general small caps are a no go for most investors at the moment but once the sale is confirmed this should fly.If the current deal is aborted there were other interested parties so not a catastrophe
Yes but it seems a no brainer to me if the Egyptian sale goes through and there is no indication it wont.There were multiple bidders anyway.I expect the proceeds to be at least the whole market cap ie £8.5m leaving Morocco in for nothing.The size of the 2 businesses are roughly equal although Morocco has more debt .So the share price seems bonkers to me but I havent mortgaged the house...yet !